Apolipoprotein E and Renal Disease

American Journal of Kidney Diseases

Volumn 43, Issue 2, 2004, Pages 223-233

  Liberopoulos, Evagelos ^a   Siamopoulos, Kostas ^a   Elisaf, Moses ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

Author keywords

Apolipoprotein E (ApoE); Continuous ambulatory peritoneal dialysis (CAPD); Hemodialysis (HD); Kidney; Renal disease; Renal failure; Transplantation

Indexed keywords

APOLIPOPROTEIN E; LIPID;

ATHEROSCLEROSIS; CARDIOVASCULAR RISK; DEGENERATIVE DISEASE; DIABETIC NEPHROPATHY; DISEASE COURSE; DISEASE SEVERITY; GENE MUTATION; GENETIC POLYMORPHISM; GLOMERULOPATHY; HUMAN; KIDNEY DISEASE; KIDNEY FUNCTION; LIPID BLOOD LEVEL; LIPOPROTEIN GLOMERULOPATHY; REVIEW; UREMIA;

EID: 0742323171     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ajkd.2003.10.013     Document Type: Article

References (103)

1. Mahley RW: Apolipoprotein E: Cholesterol transport protein with expanding role in cell biology. Science 240:622-630, 1988
2. Yamamoto T, Bujo H: Close encounters with apolipoprotein E receptors. Curr Opin Lipidol 7:298-302, 1996
3. Utermann G: Apolipoprotein E polymorphism in health and disease. Am Heart J 113:433-440, 1987
4. Utermann G, Kindermann H, Kaffarnic H, Steinmetz A: Apolipoprotein E phenotypes and hyperlipidemia. Hum Genet 65:232-236, 1984
5. Kesaniemi YA, Ehnholm C, Miettinen TA: Intestinal cholesterol absorption efficiency in man is related to apolipoprotein E phenotype. J Clin Invest 80:578-581, 1987
6. Mahley RW, Huang Y: Apolipoprotein E: from atherosclerosis to Alzheimer's disease and beyond. Curr Opin Lipidol 10:207-217, 1999
7. Hagberg JM, Wilund KR, Ferrell RE: APO E gene and gene-environment effects on plasma lipoprotein-lipid levels. Physiol Genomics 4:101-108, 2000
8. Liberopoulos E, Karabina S-A, Tselepis A, et al: Are the effects of tamoxifen on serum lipid profile modified by apolipoprotein E phenotypes? Oncology 62:115-120, 2002
9. Liberopoulos E, Pavlidis N, Elisaf M: The effect of tamoxifen therapy on serum apolipoprotein A-I level is modified by the apolipoprotein E phenotype. Clin Biochem 34:161, 2001 (letter)
10. Utermann G, Hess M, Steinmetz A: Polymorphism of apo E and occurrence of dysbetalipoproteinemia in man. Nature 269:604-607, 1977
11. Wilson PWF, Myers RH, Larson MG, Ordovas JM, Wolf PA, Schaefr EJ: Apolipoprotein E alleles, dyslipidemia, and coronary heart disease. The Framingham Offspring Study. JAMA 272:1666-1671, 1994
12. McCarron MO, Delong D, Alberts MJ: APOE genotype as a risk factor for ischemic cerebrovascular disease. A meta-analysis. Neurology 53:1308-1311, 1999
13. Curtiss LK, Boisvert WA: Apolipoprotein E and atherosclerosis. Curr Opin Lipidol 11:243-251, 2000
14. Scharf S, Wexler J, Longnecker RE, Blaufox MD: Cardiovascular disease in patients on hemodialytic therapy. Prog Cardiovasc Dis 22:343-356, 1980
15. Siamopoulos KC, Elisaf M: Is CAPD atherogenic? Perit Dial Int 17:227-231, 1997
16. Bairaktari E, Elisaf M, Tzallas C, et al: Evaluation of five methods for determining low-density lipoprotein cholesterol (LDL-C) in hemodialysis patients. Clin Biochem 34: 593-602, 2001
17. Elisaf M, Mikhailidis DP, Siamopoulos KC: Dyslipidaemia in patients with renal diseases. J Drug Dev Clin Pract 7:331-348, 1996
18. Elisaf MS, Bairaktari HT, Tziallas CS, Germanos NK, Siamopoulos KC: Atherogenic lipid and lipoprotein parameters in hemodialysis patients. Dial Transplant 24:642-650, 1995
19. Siamopoulos KC, Elisaf MS, Bairaktari HT, Pappas MB, Sferopoulos GD, Nikolakakis NG: Lipid parameters including lipoprotein(a) in patients undergoing CAPD and hemodialysis. Perit Dial Int 15:342-347, 1995
20. Elisaf MS, Dardamanis MA, Papagalanis ND, Siamopoulos KC: Lipid abnormalities in chronic uremic patients, Response to treatment with gemfibrozil. Scand J Urol Nephrol 27:101-108, 1993
21. Elisaf MS, Bairaktari HT, Tsolas OE, Siamopoulos KC: Lipoprotein(a) levels in diabetics on chronic hemodialysis. J Nephrol 8:198-205, 1995
22. Bairaktari E, Elisaf M, Tsolas O, Siamopoulos KC: Serum Lp(a) levels in patients with moderate renal failure. Nephron 79:367-368, 1998
23. Milionis HJ, Elisaf MS, Tselepis A, Bairaktari E, Karabina SA, Siamopoulos KC: Apolipoprotein (a) phenotypes and lipoprotein(a) concentrations in patients with renal failure. Am J Kidney Dis 33:1100-1106, 1999
24. Elisaf MS, Bairaktari HT, Tziallas CS, Milionis HJ, Siamopoulos KC: Increased lipoprotein(a) levels in patients with proteinuria. Cardiovasc Risk Factors 6:289-293, 1996
25. De Knijff P, Kaptein A, Boomsma D, Princen HMG, Frants RR, Havekes LM: Apolipoprotein E polymorphism affects plasma levels of lipoprotein(a). Atherosclerosis 90: 169-174, 1991
26. Milionis HJ, Elisaf MS, Karabina SAP, Bairaktari H, Tselepis AD, Siamopoulos KC: Plasma and Lp(a)-associated PAF-acetylhydrolase activity in uremic patients undergoing different dialysis procedures. Kidney Int 56:2276-2285, 1999
27. Koenig W: Update on C-reactive protein as a risk marker in cardiovascular disease. Kidney Int Suppl 84:S58-S61, 2003
28. Keane WF, Kasiske BL, O'Donnell MP: Lipids and progressive glomerulosclerosis. Am J Nephrol 8:261-271, 1988
29. Guz G, Ozdemir FN, Sezer S, et al: Effect of apolipoprotein E polymorphism on serum lipid, lipoproteins, and atherosclerosis in hemodialysis patients. Am J Kidney Dis 36:826-836, 2000
30. Feussner G, Wey S, Bommer J, Deppermann D, Grutzmacher P, Ziegler R: Apolipoprotein E phenotypes and hyperlipidemia in patients under maintenance hemodialysis. Hum Genet 88:307-312, 1992
31. Eggertsen G, Heimburger O, Stenvinkel P, Berglund L: Influence of variation at the apolipoprotein E locus on lipid and lipoprotein levels in CAPD patients. Nephrol Dial Transplant 12:141-144, 1997
32. Imura T, Kimura H, Gejyo F: Apolipoprotein E phenotypes in hemodialysis patients. Kidney Int Suppl 71:S245-S247, 1999
33. Oda H, Yorioka N, Ueda C, Kushihata S, Yamakido M: Apolipoprotein E polymorphism and renal disease. Kidney Int Suppl 71:S25-S27, 1999
34. Lerique B, Moulin B, Delpero C, Purgus R, Olmer M, Boyer J: Apolipoprotein E phenotype and hyperlipoproteinemia in nephrotic syndrome. Clin Chem 40:849-850, 1994
35. Roussos L, Floren CH, Carlson J, Svensson PJ, Wallmark A, Ekberg H: Increased prevalence of apolipoprotein E3/E4 genotype among Swedish renal transplant recipients. Nephron 83:25-30, 1999
36. Yorioka N, Nishida Y, Oda H, Watanabe T, Yamakido M: Apolipoprotein E polymorphism in IgA nephropathy. Nephron 83:246-249, 1999
37. Asami T, Ciomartan T, Hayakawa H, Uchiyama M, Tomisawa S: Apolipoprotein E ε4 allele and nephrotic glomerular diseases in children. Pediatr Nephrol 13:233-236, 1999
38. Nestel PJ, Fidge NH, Tan MH: Increased lipoprotein-remnant formation in chronic renal failure. N Engl J Med 307:329-333, 1982
39. Joven J, Vilella E: The influence of apoprotein ε2 homozygosity on nephrotic hyperlipidemia. Clin Nephrol 48:141-145, 1997
40. Ellis D, Orchard TJ, Lombardozzi S, et al: Atypical hyperlipidemia and nephropathy associated with apolipoprotein E homozygosity. J Am Soc Nephrol 6: 1170-1177, 1995
41. Feussner G, Wingen AM, Ziegler R: Type III hyperlipoproteinemia in a child with hemolytic uremic syndrome. Metabolism 39:1196-1199, 1990
42. Amatruda JM, Margolis S, Hutchins GM: Type 3 hyperlipoproteinemia with mesangial foam cells in renal glomeruli. Arch Pathol 98:51-54, 1976
43. Balson KR, Niall JF, Best JD: Glomerular lipid deposition and proteinuria in a patient with familial dysbetalipoproteinaemia. J Intern Med 240:157-159, 1996
44. Suzaki K, Kobori S, Ueno S, et al: Effects of plasmapheresis on familial type III hyperlipoproteinemia associated with glomerular lipidosis, nephrotic syndrome and diabetes mellitus. Atherosclerosis 80:181-189, 1990
45. Sakatsume M, Kadomura M, Sakata I, et al: Novel glomerular lipoprotein deposits associated with apolipoprotein E2 homozygosity. Kidney Int 59:1911-1918, 2001
46. Oda H, Yorioka N, Ueda C, Nishida Y, Yamakido M: Apolipoprotein E phenotype and renal disease. Contrib Nephrol 120:22-29, 1997
47. Choi KH; Song HY, Shin SK, et al: Influence of apolipoprotein E genotype on lipid and lipoprotein levels in continuous ambulatory peritoneal dialysis patients. Adv Perit Dial 15:243-246, 1999
48. Olmer M, Renucci JE, Planells R, Bouchouareb D, Purgus R: Preliminary evidence for a role of apolipoprotein E alleles in identifying haemodialysis patients at high vascular risk. Nephrol Dial Transplant 12:691-693, 1997
49. Lim PS, Liu CS, Hong CJ, Wei YH: Prevalence of apolipoprotein E genotypes in ischaemic cerebrovascular disease in end-stage renal disease patients. Nephrol Dial Transplant 12:1916-1920, 1997
50. Rodrigo E, Gonzalez-Lamuno D, Ruiz JC, et al: Apolipoprotein C-III and E polymorphisms and cardiovascular syndrome, hyperlipidemia, and insulin resistance in renal transplantation. Am J Transplant 2:343-348, 2002
51. Rossing P, Hougaard P, Borch-Johnsen K, Parving HH: Predictors of mortality in insulin dependent diabetes mellitus: 10 year observational follow up study. BMJ 313: 779-784, 1996
52. US Renal Data System: 2001 Annual Data Report. The National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2001
53. Borch-Johnsen K, Norgaard K, Hommel E, et al: Is diabetic nephropathy an inherited complication? Kidney Int 41:719-722, 1992
54. Araki SI, Moczulski DK, Hanna L, Scott LJ, Warram JH, Krolewski AS: APOE polymorphisms and the development of diabetic nephropathy in type 1 diabetes: Results of case-control and family-based studies. Diabetes 49:2190-2195, 2000
55. Chowdhury TA, Dyer PH, Kumar S, et al: Association of apolipoprotein ε2 aliele with diabetic nephropathy in Caucasian subjects with IDDM. Diabetes 47:278-280, 1998
56. Werle E, Fiehn W, Hasslacher C: Apolipoprotein E polymorphism and renal function in German type 1 and type 2 diabetic patients. Diabetes Care 21:994-998, 1998
57. Orchard TJ, Chang YF, Ferrell RE, Petro N, Ellis DE: Nephropathy in type 1 diabetes: A manifestation of insulin resistance and multiple genetic susceptibilities? Further evidence from the Pittsburgh Epidemiology of Diabetes Complication Study. Kidney Int 62:963-970, 2002
58. Onuma T, Laffel LMB, Angelico MC, Krolewski AS: Apolipoprotein E genotypes and risk of diabetic nephropathy. J Am Soc Nephrol 7:1075-1078, 1996
59. Hadjadj S, Gallois Y, Simard G, et al: Lack of relationship in long-term type 1 diabetic patients between diabetic nephropathy and polymorphisms in apolipoprotein epsilon, lipoprotein lipase and cholesteryl ester transfer protein (GENEDIAB Study). Nephrol Dial Transplant 15: 1971-1976, 2000
60. Tarnow L, Stehouwer CD, Emeis JJ, et al: Plasminogen activator inhibitor-1 and apolipoprotein E gene polymorphisms and diabetic angiopathy. Nephrol Dial Transplant 15:625-630, 2000
61. Soedamah-Muthu SS, Colhoun HM, Taskinen MR, Idzior-Walus B, Fuller JH: Differences in HDL-cholesterol: ApoA-I + apoA-II ratio and apoE phenotype with albuminuric status in type I diabetic patients. Diabetologia 43:1353-1359, 2000
62. Schachter F, Faure-Delanef L, Guenot F, et al: Genetic associations with human longevity at the APOE and ACE loci. Nat Genet 6:29-32, 1994
63. Eto M, Saito M, Okada M, et al: Apolipoprotein E genetic polymorphism, remnant lipoproteins, and nephropathy in type 2 diabetic patients. Am J Kidney Dis 40:243-251, 2002
64. Hsieh MC, Lin SR, Yang YC, Chen HC, Lin JN, Shin SJ: Higher frequency of apolipoprotein E2 allele in type 2 diabetic patients with nephropathy in Taiwan. J Nephrol 15:368-373, 2002
65. Eto M, Horita K, Morikawa A, et al: Increased frequency of apolipoprotein ε2 allele in non-insulin dependent diabetic (NIDDM) patients with nephropathy. Clin Genet 48:288-292, 1995
66. Ha SK, Park HS, Kim KW, et al: Association between apolipoprotein E polymorphism and macroalbuminuria in patients with non-insulin dependent diabetes mellitus. Nephrol Dial Transplant 14:2144-2149, 1999
67. Boize R, Benhamou PY, Corticelli P, Valenti K, Bosson JL, Halimi S: ApoE polymorphism and albuminuria in diabetes mellitus: A role for LDL in the development of nephropathy in NIDDM? Nephrol Dial Transplant 13:72-75, 1998
68. Kimura H, Suzuki Y, Gejyo F, et al: Apolipoprotein E4 reduces risk of diabetic nephropathy in patients with NIDDM. Am J Kidney Dis 31:666-673, 1998
69. Lehtinen S, Rantalaiho V, Wirta O, et al: Apolipoprotein E gene polymorphism, hypercholesterolemia and glomerular filtration rate in type 2 diabetic subjects: A 9-year follow-up study. J Biomed Sci 10:260-265, 2003
70. Farrangiana T, Churg J: Renal lipidoses: A review. Hum Pathol 18:661-679, 1987
71. Oikawa S, Suzuki N, Sakuma E, et al: Abnormal lipoprotein and apolipoprotein pattern in lipoprotein glomerulopathy. Am J Kidney Dis 18:553-558, 1991
72. Siato T, Sato H, Oikawa S, et al: Lipoprotein glomerulopathy: Report of a normolipidemic case and review of the literature. Am J Nephrol 13:64-68, 1993
73. Maruyama K, Arai H, Ogawa T, Tomizawa S, Morikawa A: Lipoprotein glomerulopathy: A pediatric case report. Pediatr Nephrol 11:213-214, 1997
74. Zhang P, Malaton R, Kaplan L, Kumar A, Gallo G: Lipoprotein glomerulopathy: First report in a Chinese male. Am J Kidney Dis 24:942-950, 1994
75. Saito T, Ishigaki Y, Oikawa S, Yamamoto TT: Etiologic significance of apolipoprotein E mutations in lipoprotein glomerulopathy. Trend Cardiovasc Med 12:67-70, 2002
76. Saito T, Oikawa S, Sato H, Sato T, Ito S, Sasaki J: Lipoprotein glomerulopathy: Significance of lipoprotein and ultrastuctural features. Kidney Int Suppl 71:S37-S41, 1999
77. Saito T, Oikawa S, Sato H, Sasaki J: Lipoprotein glomerulopathy: Renal lipidosis induced by novel apolipoprotein E variants. Nephron 83:193-201, 1999
78. Saito T, Oikawa S, Sato H, Chiba J: Lipoprotein glomerulopathy and its pathogenesis. Contrib Nephrol 120: 30-38, 1997
79. Karet FE, Lifton RP: Lipoprotein glomerulopathy: A new role for apolipoprotein E? J Am Soc Nephrol 8:840-842, 1997
80. Oikawa S, Matsunaga A, Saito T, et al: Apolipoprotein E Sendai (Arginine 145→proline): A new variant associated with lipoprotein glomerulopathy. J Am Soc Nephrol 8:820-823, 1997
81. Ando M, Sasaki J, Hua H, et al: A novel 18-amino acid deletion in apolipoprotein E associated with lipoprotein glomerulopathy. Kidney Int 56:1317-1323, 1999
82. Konishi K, Saruta T, Kuramochi S, et al: Association of a novel 3-amino acid deletion of apolipoprotein E (Apo E Tokyo) with lipoprotein glomerulopathy. Nephron 83:214-218, 1999
83. Matsunaga A, Sasaki J, Komatsu T, et al: A novel apolipoprotein E mutation, E2 (Arg25Cys), in lipoprotein glomerulopathy. Kidney Int 56:421-427, 1999
84. Ogawa T, Maruyama K, Hattori H, et al: A new variant of apolipoprotein E (apo E Maebashi) in lipoprotein glomerulopathy. Pediatr Nephrol 14:149-151, 2000
85. Ishigaki Y, Oikawa S, Suzuki T, et al: Virus-mediated transduction of apolipoprotein E (ApoE)-Sendai develops lipoprotein glomerulopathy in ApoE-deficient mice. J Biol Chem 275:31269-31273, 2000
86. Hoffmann M, Scharnagl H, Panagiotou E, Banghard W, Wieland H, Marz W: Diminished LDL receptor and high heparin binding of apolipoprotein E2 Sendai associated with lipoprotein glomerulopathy. J Am Soc Nephrol 12:524-530, 2001
87. Murano T, Matsumura R, Misawa Y, et al: Interaction of endothelial cells and triglyceride-rich lipoproteins with apolipoprotein E (Arg→Cys) from a patient with lipoprotein glomerulopathy. Metabolism 51:201-205, 2002
88. Ieiri N, Hotta O, Taguma Y: Resolution of typical lipoprotein glomerulopathy by intensive lipid-lowering therapy. Am J Kidney Dis 41:244-249, 2003
89. Attila G, Noyan A, Karabay Bayazit A, Acarturk E, Anarat A: Apolipoprotein E polymorphism in childhood nephrotic syndrome. Pediatr Nephrol 17:359-362, 2002
90. Kohlmeier M, Saupe J, Schaefer K, Asmus G: Bone fracture history and prospective bone fracture risk of hemodialysis patients are related to apolipoprotein E genotype. Calcif Tissue Int 62:278-281, 1998
91. Saupe J, Shearer MJ, Kohlmeier M: Phylloquinone transport and its influence on γ-carboxyglutamate residues of osteocalcin in patients on maintenance hemodialysis. Am J Clin Nutr 58:204-208, 1993
92. Gejyo F, Kimura H, Suzuki S, Miyazaki R, Naiki H, Nakakuki K: Apolipoprotein E and alpha 1-antichymotrypsin in dialysis-related amyloidosis. Kidney Int Suppl 62:S75-S78, 1997
93. Chew STH, Newman MF, White WD, et al: Preliminary report on the association of apolipoprotein E polymorphisms, with postoperative peak serum creatinine concentrations in cardiac surgical patients. Anesthesiology 93:325-331, 2000
94. Chen G, Paka L, Kako Y, Singhal P, Duan W, Pillarisetti S: A protective role for kidney apolipoprotein E. Regulation of mesangial cell proliferation and matrix expansion. J Biol Chem 276:49142-49147, 2001
95. Wen M, Segerer S, Dantas M, et al: Renal injury in apolipoprotein E-deficient mice. Lab Invest 82:999-1006, 2002
96. Gervais M, Pons S, Nicoletti A, Cosson C, Giudicelli JF, Richer C: Fluvastatin prevents renal dysfunction and vascular NO deficit in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 23:183-189, 2003
97. Bruneval P, Bariety J, Belair M-F, et al: Mesangial expansion associated with glomerular endothelial cell activation and macrophage recruitment is developing in hyperlipidaemic apoE null mice. Nephrol Dial Transplant 17:2099-2107, 2002
98. Blue ML, Williams DL, Zucker S, Khan SA, Blum CB: Apolipoprotein E synthesis in human kidney, adrenal gland, and liver. Proc Natl Acad Sci U S A 80:283-287, 1983
99. Alsayed N, Rebourcet R: Abnormal concentrations of CII, CIII, and E apolipoproteins among apolipoprotein B-containing, B-free, and A-I-containing lipoprotein particles in hemodialysis patients. Clin Chem 37:387-393, 1991
100. Kandoussi AM, Hugue V, Parra HJ, et al: Apolipoprotein AI and apolipoprotein B containing particle analysis in normolipidemic hemodialyzed patients: Evidence of free apolipoprotein E. Am J Nephrol 16:287-292, 1996
101. Takemura T, Yoshioka K, Aya N, et al: Apolipoproteins and lipoprotein receptors in glomeruli in human kidney diseases. Kidney Int 43:918-927, 1993
102. Sato H, Suzuki S, Kobayashi H, Ogino S, Inomata A, Arakawa M: Immunohistological localization of apolipoproteins in the glomeruli in renal disease: Specifically apoB and apoE. Clin Nephrol 36:127-133, 1991
103. Grone HJ, Walli AK, Grone E, Kramer A, Clemens MR, Seidel D: Receptor mediated uptake of apoB and apoE rich lipoproteins by human glomerular epithelial cells. Kidney Int 37:1449-1459, 1990